论文部分内容阅读
作者采用噻唑蓝（ＭＴＴ）法，对人体手术切除的原发性肝细胞癌的新鲜标本，作顺铂、卡铂、丝裂霉素、阿霉累和５氟脲嘧啶的抗癌敏感药物试验，试图预测出针对性较强的化疗药物，为临床科学合理地选择用药提供可靠依据。作者共检测４９例原发性肝细胞癌，结果显示，对两种药物敏感者１４例，占２８．６％，对其它药种敏感者很少，敏感药物顺序与临床治疗结果大致相符。此结果可作临床药物选择时参考，在实体瘤药敏试验中，ＭＴＴ法仍然可行。
The authors used thiazolyl blue (MTT) method for fresh specimens of primary hepatocellular carcinoma that were surgically removed from the human body as anti-cancer sensitive drugs for cisplatin, carboplatin, mitomycin, micorlemate, and 5-fluorouracil In order to predict a more targeted chemotherapeutic drug, it provides a reliable basis for rational selection of drugs for clinical science. The authors detected 49 cases of primary hepatocellular carcinoma. The results showed that 14 cases were sensitive to the two drugs, accounting for 28.6%, and few were sensitive to other drug types. The sequence of sensitive drugs was generally consistent with the clinical treatment results. This result can be used as reference for clinical drug selection. MTT assay is still feasible in solid susceptibility testing.